In this sense, EZH2 inhibitors were discarded as potential therapeutic strategy since they drive FLT3 signaling induction, thus failing to block t(4;11) pro-B-ALL cells proliferation. This evidence concerns the gene FLT3 and acute lymphoblastic leukemia.